Skip to main content
. 2020 Jul 23;11:1537. doi: 10.3389/fimmu.2020.01537

Table 1.

Patients and donors, transplantation procedure, economic, and socioeconomic indices.

Patient and procedure characteristics
N 4,152
Median patient age, years (range) 53 (18–79)
Median donor age, years (range) 37 (5–77)
    Missing data 2,344
Median year of transplantation (range) 2,013 (2,011–2,015)
Median interval from diagnosis to transplantation, range (days) 296 (7–13,058)
Donor type
    HLA-identical sibling 1,328 (32%)
    Unrelated 2,824 (68%)
      HLA-matched 1,491 (72%)
      HLA-mismatched 576 (28%)
      Missing data 757
Donor/recipient gender
    Female to male 851 (21%)
    Other combination 3,255 (79%)
    Missing data 46
Donor/recipient CMV serological status
    Negative/negative 1,089 (27.5%)
    Other 2,871 (72.5%)
    Missing data 192
Diagnosis
    Acute leukemia 2,091 (50%)
    Chronic leukemia 432 (10%)
    Lymphoma 560 (14%)
    Plasma cell disorders 185 (5%)
    MDS/MPN 884 (21%)
Disease risk status at alloHCT*
    High risk 1,387 (35%)
    Low/moderate risk 2,625 (65%)
Missing 140
Previous autoHCT
    No 3,645 (88%)
    Yes 507 (12%)
Source of stem cells
    Bone marrow 356 (9%)
    Peripheral blood 3,796 (91%)
In vivo T-cell depletion
    No 1,870 (45.7%)
    Yes 2,223 (54.3%)
Conditioning intensity
    Myeloablative 2,047 (49%)
    Reduced intensity 2,096 (51%)
    Missing data 9
Type of conditioning
    Chemotherapy-based 3,027 (73%)
    Total body irradiation-based 1,122 (27%)
    Missing data 3
Economic and socioeconomic indices Median (range)
Current HCE, range (Euro) 4,955 (465–9,720)
Median HCE as % of GDP 11.1 (3.7–12)
Median private HCE, range (Euro) 1,087 (103–3,168)
Median public HCE, range (Euro) 3,868 (308–8,285)
Median no. teams per 1 million inhabitants 1.09 (0.03–1.62)
Median no. teams per 1,000 km2 0.20 (0.00–0.59)
Median HDI 0.88 (0.74–0.94)
Median no. alloHCT** between 2004 and 2008 13.5 (2.0–35.0)

MDS indicates myelodysplastic syndrome; MPN, myeloproliferative neoplasms; HCE health care expenditure; HDI, human development index; GDP, gross domestic product per capita.

*

For the purpose of this study the definition of high risk related to underlying disease was defined as follows: acute leukemias and lymphomas with active disease, chronic myeloid leukemia in acceleration phase or in blast crisis, myelodysplastic syndromes and myeloproliferative neoplasms not responding to preceding therapy.

**

Refers to transplantation procedures according to selection criteria chosen for this study.